Real-time analysis of P-glycoprotein-mediated drug transport across primary intestinal epithelium three-dimensionally cultured in vitro

Biochemical and Biophysical Research Communications

Volumn 419, Issue 2, 2012, Pages 238-243

  Mizutani, Tomohiro ^a   Nakamura, Tetsuya ^a   Morikawa, Ryo ^a   Fukuda, Masayoshi ^a   Mochizuki, Wakana ^a   Yamauchi, Yuhki ^a   Nozaki, Kengo ^a   Yui, Shiro ^a   Nemoto, Yasuhiro ^a   Nagaishi, Takashi ^a   Okamoto, Ryuichi ^a   Tsuchiya, Kiichiro ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cell membrane permeability; Drug transport; Intestinal absorption; Live imaging; P glycoprotein; Primary culture

Indexed keywords

GLYCOPROTEIN P; MESSENGER RNA; RHODAMINE 123; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BIOACCUMULATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG TRANSPORT; EXPERIMENTAL MODEL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMALL INTESTINE MUCOSA; TISSUE CULTURE; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; FLUORESCENT DYES; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACOKINETICS; RHODAMINE 123; VERAPAMIL;

EID: 84862802229     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.155     Document Type: Article

References (24)

1. Takano M., Yumoto R., Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 2006, 109:137-161.
2. Kunta J.R., Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug. Metab. 2004, 5:109-124.
3. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 1987, 84:7735-7738.
4. Hsing S., Gatmaitan Z., Arias I.M. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992, 102:879-885.
5. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 2000, 38:69-74.
6. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101:289-294.
7. Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H.J., Hop C.E., Keohane C.A., Ly V.T., Strauss J.R., Wang R.W., Wang Z., Pippert T.R., Umbenhauer D.R. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 1999, 27:581-587.
8. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 1997, 94:2031-2035.
9. van Asperen J., van Tellingen O., Beijnen J.H. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 2000, 28:264-267.
10. Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96:736-749.
11. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 1993, 268:14991-14997.
12. Yumoto R., Murakami T., Nakamoto Y., Hasegawa R., Nagai J., Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther. 1999, 289:149-155.
13. Takano M., Hasegawa R., Fukuda T., Yumoto R., Nagai J., Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur. J. Pharmacol. 1998, 358:289-294.
14. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol succinate (TPGS). Pharm. Res. 1999, 16:1550-1556.
15. van De Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44:1313-1333.
16. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1:385-401.
17. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
18. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell Biol. 1989, 9:1346-1350.
19. Perloff M.D., Stormer E., von Moltke L.L., Greenblatt D.J. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm. Res. 2003, 20:1177-1183.
20. Lee J.S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 1994, 46:627-638.
21. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175:880-885.
22. Kim D.C., Burton P.S., Borchardt R.T. A correlation between the permeability characteristics of a series of peptides using an in vitro cell culture model (Caco-2) and those using an in situ perfused rat ileum model of the intestinal mucosa. Pharm. Res. 1993, 10:1710-1714.
23. Ribadeneira M.D., Aungst B.J., Eyermann C.J., Huang S.M. Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption. Pharm. Res. 1996, 13:227-233.
24. Stewart B.H., Chan O.H., Lu R.H., Reyner E.L., Schmid H.L., Hamilton H.W., Steinbaugh B.A., Taylor M.D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm. Res. 1995, 12:693-699.